UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process.

SLE is the most common form of lupus and affects up to 300,000 people in the US, disproportionately affecting African-American, Hispanic and Asian populations. Image Phil Taylor ...

In a multicenter, cross-sectional study, Yee et al. have determined the construct and criterion validity of the British Isles Lupus Assessment Group 2004 index (BILAG-2004), a revision of the ...

This is alongside a GLP capability and support for classical SPE and SLE column consumable formats. Complete with dedicated SPE and SLE methods the new system comes pre-programmed with a host of ...

A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus (SLE) with persistently active disease (PAD). Researchers found that both ...